#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary amyloidosis Isodicentric chromosome 15 syndrome Fibrosarcoma Retinoblastoma Hereditary neuropathic amyloidosis Fontan procedure Antisynthetase syndrome Pulmonary alveolar haemorrhage Acute leukaemia Myelin oligodendrocyte glycoprotein antibody-associated disease Von Willebrand's disease B-cell lymphoma Astrocytoma Transitional cell carcinoma Hypoxic-ischaemic encephalopathy More trials…

    Learn about Rare Diseases

    Osteosarcoma – Treatment Immunodeficiency congenital – Treatment KBG syndrome – Trials in Disease Behcet’s syndrome Glomerulonephritis membranous – Basic Information Myelodysplastic syndrome – Trials in Disease Antithrombin III deficiency – Diagnostics Brain stem glioma – Diagnostics Amyotrophic lateral sclerosis – Treatment Stevens-Johnson syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trimetazidine Dihydrochloride Rbp030.2 Rituximab Asfotase Alfa Hydrocortisone Hemisuccinate Amantadine Hydrochloride Air, Medicinal Ulonivirine Lithium Sulphate, Anhydrous AVTX-009 Heterodimeric Interleukin-15 Belimumab Dabrafenib Mesylate Remestemcel Taletrectinib Sulfasalazine Oxygen Lacnotuzumab Dotatate Bromocriptine More therapies…

    Learn about Your Condition

    Juvenile idiopathic arthritis Interstitial lung disease Meniscus operation Malignant mast cell neoplasm Salivary gland cancer Extra-osseous Ewing's sarcoma Gastric cancer recurrent Osteonecrosis of jaw Mitochondrial DNA depletion Rectal cancer Pancreatitis chronic Lower limb fracture Oesophageal cancer metastatic Craniosynostosis Eyelid ptosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina…

Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie

Ul. Fryderyka Szopena 2, Rzeszow, 35-055, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

    Recruiting

    2 1
    Investigated Drugs:
    • Ro7790121
    France Germany Italy Poland Spain

  • A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Barzolvolimab
    • Epinephrine
    Belgium Bulgaria Croatia Czechia Denmark France +10

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Face and Neck Atopic Dermatitis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Lebrikizumab
    Denmark France Germany Poland Portugal Spain

  • Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

    Not yet recruiting

    2 1
    Bulgaria Czechia Germany Italy Poland

  • Pharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Nemolizumab
    Poland

  • Dapagliflozin for Primary Cardioprotection in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation – A Randomized Phase 2 Study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dapagliflozin
    Poland

  • A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Lichen sclerosus
    France Germany Italy Poland Spain

  • A study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Zasocitinib
    France Germany The Netherlands Poland

  • Study on the Effectiveness and Safety of ANB032, Hydrocortisone, and Alclometasone Dipropionate for Patients with Moderate to Severe Atopic Dermatitis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Alclometasone Dipropionate
    • Anb032
    • Hydrocortisone
    Czechia Poland
Previous Page
1 2 3 4 5 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!